Name: Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Cut to $225.00 by Analysts at Needham & Company LLC
Brand: rivertonroll.com
SKU: rivertonroll-com-30
Availability: OnlineOnly

critic

Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Cut to $225.00 by Analysts at Needham & Company LLC

preview

Skip to main contentPosted by onhad its price objective cut by Needham &amp; Company LLC from $226.00 to $225.00 in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.Other research analysts have also issued reports about the stock. Raymond James assumed coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, September 28th. They set a market perform rating for the company. HC Wainwright restated a buy rating and set a $204.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, August 11th. Royal Bank of Canada reduced their price target on shares of Jazz Pharmaceuticals from $203.00 to $201.00 and set an outperform rating for the company in a research report on Thursday, August 10th. Bank of America boosted their price target on shares of Jazz Pharmaceuticals from $204.00 to $217.00 and gave the company a buy rating in a research report on Thursday, August 10th. Finally, Cantor Fitzgerald restated an overweight rating and set a $180.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, August 22nd. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of Buy and a consensus target price of $204.83.Get Our Latest Research Report on Jazz PharmaceuticalsShares of JAZZ stock opened at $116.52 on Thursday. The company’s fifty day simple moving average is $131.51 and its two-hundred day simple moving average is $131.75. The company has a debt-to-equity ratio of 1.61, a current ratio of 3.18 and a quick ratio of 2.49. Jazz Pharmaceuticals has a 1 year low of $116.32 and a 1 year high of $160.96. The stock has a market capitalization of $7.35 billion, a price-to-earnings ratio of 132.41, a PEG ratio of 0.92 and a beta of 0.73.Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $3.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.68 by $0.15. Jazz Pharmaceuticals had a net margin of 2.11% and a return on equity of 22.52%. The business had revenue of $957.32 million for the quarter, compared to analysts’ expectations of $952.44 million. As a group, analysts anticipate that Jazz Pharmaceuticals will post 15.57 earnings per share for the current year.In related news, Director Rick E. Winningham sold 1,241 shares of the company’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $138.16, for a total value of $171,456.56. Following the completion of the transaction, the director now directly owns 10,444 shares in the company, valued at $1,442,943.04. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Neena M. Patil sold 750 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $139.59, for a total transaction of $104,692.50. Following the completion of the transaction, the executive vice president now directly owns 30,686 shares of the company’s stock, valued at $4,283,458.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Rick E. Winningham sold 1,241 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $138.16, for a total transaction of $171,456.56. Following the transaction, the director now directly owns 10,444 shares of the company’s stock, valued at $1,442,943.04. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,791 shares of company stock worth $534,726. Corporate insiders own 4.40% of the company’s stock.A number of institutional investors have recently bought and sold shares of the stock. Sequoia Financial Advisors LLC raised its stake in Jazz Pharmaceuticals by 5.7% in the first quarter. Sequoia Financial Advisors LLC now owns 1,376 shares of the specialty pharmaceutical company’s stock worth $201,000 after buying an additional 74 shares in the last quarter. Aviance Capital Partners LLC increased its stake in shares of Jazz Pharmaceuticals by 0.8% during the second quarter. Aviance Capital Partners LLC now owns 10,296 shares of the specialty pharmaceutical company’s stock valued at $1,276,000 after purchasing an additional 80 shares in the last quarter. Massmutual Trust Co. FSB ADV increased its stake in shares of Jazz Pharmaceuticals by 65.6% during the third quarter. Massmutual Trust Co. FSB ADV now owns 202 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 80 shares in the last quarter. Platinum Investment Management Ltd. increased its stake in shares of Jazz Pharmaceuticals by 13.1% during the second quarter. Platinum Investment Management Ltd. now owns 697 shares of the specialty pharmaceutical company’s stock valued at $86,000 after purchasing an additional 81 shares in the last quarter. Finally, Captrust Financial Advisors increased its stake in shares of Jazz Pharmaceuticals by 2.4% during the first quarter. Captrust Financial Advisors now owns 3,707 shares of the specialty pharmaceutical company’s stock valued at $577,000 after purchasing an additional 86 shares in the last quarter. 88.15% of the stock is owned by institutional investors.(Get Free Report)Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.Receive News &amp; Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.Performance Food Group Given Overweight Rating at StephensIQE Trading Up 6%University Bancorp Stock Price Down 2.4%Crescent Point Energy Corp. Director Craig Stephen Bryksa Acquires 10,000 Shares of StockJazz Pharmaceuticals Price Target Cut to $225.00 by Analysts at Needham &amp; Company LLCSangoma Technologies Receives Hold Rating from Canaccord Genuity GroupComplete the form below to receive the latest headlines and analysts' recommendations for Jazz Pharmaceuticals with MarektBeat's free daily email newsletter:

Skip to main contentPosted by onhad its price objective cut by Needham &amp; Company LLC from $226.00 to $225.00 in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.Other research analysts have also issued reports about the stock. Raymond James assumed coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, September 28th. They set a market perform rating for the company. HC Wainwright restated a buy rating and set a $204.00 price target on shares of Jazz...

Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Cut to $225.00 by Analysts at Needham & Company LLC

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS